The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Anti-tuberculosis Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in the emerging economies.
The global Anti-tuberculosis Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Anti-tuberculosis Therapeutics in various end use industries. The expanding demands from the Hospitals and Clinics, Government Agencies, Non-Profit Organizations and Others, are propelling Anti-tuberculosis Therapeutics market. Isoniazid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Rifampin segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti-tuberculosis Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti-tuberculosis Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti-tuberculosis Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti-tuberculosis Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti-tuberculosis Therapeutics covered in this report include Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca and Bayer, etc.
The global Anti-tuberculosis Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Lupin
Macleods Pharmaceuticals
Otsuka Pharmaceutical
Johnson & Johnson
Pfizer
Novartis
Abbott
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline
Merck
Sanofi
Global Anti-tuberculosis Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti-tuberculosis Therapeutics market, Segment by Type:
Isoniazid
Rifampin
Ethambutol
Pyrazinamide
Otherr
Global Anti-tuberculosis Therapeutics market, by Application
Hospitals and Clinics
Government Agencies
Non-Profit Organizations
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Anti-tuberculosis Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in the emerging economies.
The global Anti-tuberculosis Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Anti-tuberculosis Therapeutics in various end use industries. The expanding demands from the Hospitals and Clinics, Government Agencies, Non-Profit Organizations and Others, are propelling Anti-tuberculosis Therapeutics market. Isoniazid, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Rifampin segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti-tuberculosis Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti-tuberculosis Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti-tuberculosis Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti-tuberculosis Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti-tuberculosis Therapeutics covered in this report include Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca and Bayer, etc.
The global Anti-tuberculosis Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Lupin
Macleods Pharmaceuticals
Otsuka Pharmaceutical
Johnson & Johnson
Pfizer
Novartis
Abbott
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline
Merck
Sanofi
Global Anti-tuberculosis Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti-tuberculosis Therapeutics market, Segment by Type:
Isoniazid
Rifampin
Ethambutol
Pyrazinamide
Otherr
Global Anti-tuberculosis Therapeutics market, by Application
Hospitals and Clinics
Government Agencies
Non-Profit Organizations
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Anti-tuberculosis Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Anti-tuberculosis Therapeutics
1.1 Anti-tuberculosis Therapeutics Market Overview
1.1.1 Anti-tuberculosis Therapeutics Product Scope
1.1.2 Anti-tuberculosis Therapeutics Market Status and Outlook
1.2 Global Anti-tuberculosis Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Anti-tuberculosis Therapeutics Market Size by Region (2018-2029)
1.4 Global Anti-tuberculosis Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Anti-tuberculosis Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Anti-tuberculosis Therapeutics Market Size (2018-2029)
1.6.1 North America Anti-tuberculosis Therapeutics Market Size (2018-2029)
1.6.2 Europe Anti-tuberculosis Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Anti-tuberculosis Therapeutics Market Size (2018-2029)
1.6.4 Latin America Anti-tuberculosis Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Anti-tuberculosis Therapeutics Market Size (2018-2029)
2 Anti-tuberculosis Therapeutics Market by Type
2.1 Introduction
2.1.1 Isoniazid
2.1.2 Rifampin
2.1.3 Ethambutol
2.1.4 Pyrazinamide
2.1.5 Otherr
2.2 Global Anti-tuberculosis Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Anti-tuberculosis Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Anti-tuberculosis Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Anti-tuberculosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Anti-tuberculosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Anti-tuberculosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Anti-tuberculosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Anti-tuberculosis Therapeutics Revenue Breakdown by Type (2018-2029)
3 Anti-tuberculosis Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and Clinics
3.1.2 Government Agencies
3.1.3 Non-Profit Organizations
3.1.4 Others
3.2 Global Anti-tuberculosis Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Anti-tuberculosis Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Anti-tuberculosis Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Anti-tuberculosis Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Anti-tuberculosis Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Anti-tuberculosis Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Anti-tuberculosis Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Anti-tuberculosis Therapeutics Revenue Breakdown by Application (2018-2029)
4 Anti-tuberculosis Therapeutics Competition Analysis by Players
4.1 Global Anti-tuberculosis Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-tuberculosis Therapeutics as of 2022)
4.3 Date of Key Players Enter into Anti-tuberculosis Therapeutics Market
4.4 Global Top Players Anti-tuberculosis Therapeutics Headquarters and Area Served
4.5 Key Players Anti-tuberculosis Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Anti-tuberculosis Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Lupin
5.1.1 Lupin Profile
5.1.2 Lupin Main Business
5.1.3 Lupin Anti-tuberculosis Therapeutics Products, Services and Solutions
5.1.4 Lupin Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Lupin Recent Developments
5.2 Macleods Pharmaceuticals
5.2.1 Macleods Pharmaceuticals Profile
5.2.2 Macleods Pharmaceuticals Main Business
5.2.3 Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Products, Services and Solutions
5.2.4 Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Macleods Pharmaceuticals Recent Developments
5.3 Otsuka Pharmaceutical
5.3.1 Otsuka Pharmaceutical Profile
5.3.2 Otsuka Pharmaceutical Main Business
5.3.3 Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Products, Services and Solutions
5.3.4 Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Johnson & Johnson Recent Developments
5.4 Johnson & Johnson
5.4.1 Johnson & Johnson Profile
5.4.2 Johnson & Johnson Main Business
5.4.3 Johnson & Johnson Anti-tuberculosis Therapeutics Products, Services and Solutions
5.4.4 Johnson & Johnson Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Johnson & Johnson Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Anti-tuberculosis Therapeutics Products, Services and Solutions
5.5.4 Pfizer Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Anti-tuberculosis Therapeutics Products, Services and Solutions
5.6.4 Novartis Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 Abbott
5.7.1 Abbott Profile
5.7.2 Abbott Main Business
5.7.3 Abbott Anti-tuberculosis Therapeutics Products, Services and Solutions
5.7.4 Abbott Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Abbott Recent Developments
5.8 AstraZeneca
5.8.1 AstraZeneca Profile
5.8.2 AstraZeneca Main Business
5.8.3 AstraZeneca Anti-tuberculosis Therapeutics Products, Services and Solutions
5.8.4 AstraZeneca Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 AstraZeneca Recent Developments
5.9 Bayer
5.9.1 Bayer Profile
5.9.2 Bayer Main Business
5.9.3 Bayer Anti-tuberculosis Therapeutics Products, Services and Solutions
5.9.4 Bayer Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Bayer Recent Developments
5.10 Eli Lilly
5.10.1 Eli Lilly Profile
5.10.2 Eli Lilly Main Business
5.10.3 Eli Lilly Anti-tuberculosis Therapeutics Products, Services and Solutions
5.10.4 Eli Lilly Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Eli Lilly Recent Developments
5.11 GlaxoSmithKline
5.11.1 GlaxoSmithKline Profile
5.11.2 GlaxoSmithKline Main Business
5.11.3 GlaxoSmithKline Anti-tuberculosis Therapeutics Products, Services and Solutions
5.11.4 GlaxoSmithKline Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 GlaxoSmithKline Recent Developments
5.12 Merck
5.12.1 Merck Profile
5.12.2 Merck Main Business
5.12.3 Merck Anti-tuberculosis Therapeutics Products, Services and Solutions
5.12.4 Merck Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 Merck Recent Developments
5.13 Sanofi
5.13.1 Sanofi Profile
5.13.2 Sanofi Main Business
5.13.3 Sanofi Anti-tuberculosis Therapeutics Products, Services and Solutions
5.13.4 Sanofi Anti-tuberculosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Sanofi Recent Developments
6 North America
6.1 North America Anti-tuberculosis Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Anti-tuberculosis Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Anti-tuberculosis Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Anti-tuberculosis Therapeutics Market Dynamics
11.1 Anti-tuberculosis Therapeutics Industry Trends
11.2 Anti-tuberculosis Therapeutics Market Drivers
11.3 Anti-tuberculosis Therapeutics Market Challenges
11.4 Anti-tuberculosis Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
